ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

ClinicalTrials.gov ID: NCT04218084

Public ClinicalTrials.gov record NCT04218084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)

Study identification

NCT ID
NCT04218084
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
236 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Voxelotor Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 14 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 10, 2020
Primary completion
Jan 17, 2024
Completion
Nov 5, 2024
Last update posted
Mar 9, 2026

2020 – 2024

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Children's National Medical Center Washington D.C. District of Columbia 20010
University of Miami Miami Florida 33136
Children's Healthcare of Atlanta: Hughes Spalding Atlanta Georgia 30303
Boston Children's Hospital - Clinical Research Pharmacy Boston Massachusetts 02115
Boston Children's Hospital Boston Massachusetts 02115
University of Mississippi Medical Center Jackson Mississippi 39216
The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Medical University of South Carolina: Investigational Drug Services Charleston South Carolina 29425
Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital Charleston South Carolina 29425
Medical University of South Carolina Charleston South Carolina 29425
Texas Children's Hospital - Investigational Pharmacy Houston Texas 77030
Texas Children's Hospital- Wallace Tower Houston Texas 77030
Texas Children's Hospital Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04218084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04218084 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →